Conflict of interest statement: There are no conflicts of interest.185. South Asian J Cancer. 2018 Apr-Jun;7(2):106-109. doi: 10.4103/sajc.sajc_112_18.Practical consensus recommendation on when to do BRCA testing.Parikh PM(1), Wadhwa J(2), Minhas S(3), Gupta A(4), Mittal S(5), Ranjan S(6),Mehta P(7), Singh R(8), Kataria SP(9), Salim S(10), Ahmed M(11), Aggarwal S(3).Author information: (1)Department of Oncology, Shalby Cancer and Research Institute, Mumbai,Maharashtra, India.(2)Department of Medical Oncology, Medanta Hospital, Gurugram, Haryana, India.(3)Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India.(4)Department of Radiation Oncology, Safdarjung Hospital, New Delhi, India.(5)Department of Medical Oncology, Action Balajee Cancer Center, New Delhi,India.(6)Department of Medicine, INHS Sanjivani, Kochi, Kerala, India.(7)Department of Medical Oncology, Asian Institute of Medical Sciences,Faridabad, Haryana, India.(8)Department of Medical Oncology, Artemis Hospital, Gurugram, Haryana, India.(9)Department of Medical Oncology, Safdarjung Hospital, New Delhi, India.(10)Department of Oncology, Hakim Sanaullah Cancer Center, Baramulla, Jammu andKashmir, India.(11)Department of Radiation Oncology, Jolly Grant Himalayan Institute, Dehradoon,Uttarakhand, India.BRCA-mutation associated breast cancer and to future cancer risks and sensitivityto systemic therapies. Now that rapid genetic testing for BRCA1 and BRCA2mutations is available, BRCA mutation status can be considered when makingtreatment and prevention decisions for BRCA testing, BRCA mutation carriers with breast cancer. Expert group used data from published literature, practicalexperience, and opinion of a large group of academic oncologists, to arrive atpractical consensus recommendations for use by the community oncologists.DOI: 10.4103/sajc.sajc_112_18 PMCID: PMC5909285PMID: 29721474 